Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Release Date: March 31, 2025

Expiration Date: March 31, 2026

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in non–small cell lung cancer (NSCLC). In this educational program, these experts provide evidence-based strategies for managing unresectable and metastatic NSCLC. Through case-based learning, participants explore key clinical trials, molecular testing applications, and treatment sequencing with the aim of enhancing clinical decision-making and improving outcomes for patients with advanced NSCLC.

This educational activity is an archive of the live symposium held on February 22, 2025.

Target Audience

This educational activity is directed toward medical oncologists, pathologists, molecular pathologists, and thoracic surgeons.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Review evidence-based approaches to managing unresectable NSCLC, including the integration of immunotherapy and targeted therapies in unresectable settings
• Analyze findings from key trials to assess the potential impact of novel therapies and combinations on clinical outcomes in unresectable and metastatic NSCLC
• Discuss the role of molecular profiling in guiding treatment for EGFR-mutant NSCLC and strategies to address resistance mechanisms such as MET amplification and HER3 overexpression
• Explore patient selection, therapy sequencing, and the management of adverse events to optimize individualized care for patients with EGFR-mutant or immunotherapy-eligible NSCLC